Mataya Robinson

Mataya Robinson serves as a key procurement lead within the National Cancer Institute, supporting the agency’s mission to accelerate cancer research through advanced scientific infrastructure and diagnostic innovation. Responsible for managing complex acquisitions of high-performance research tools, genomic sequencing platforms, and translational diagnostics, Robinson ensures that contracting strategies align with NIH’s strategic priorities in precision medicine and molecular oncology. Their work bridges scientific demand with federal acquisition compliance, facilitating timely procurement of mission-critical technologies for laboratory and clinical research environments. Robinson maintains a primary working relationship with Roche Diagnostics Corporation, reflecting a consistent reliance on industry leaders in oncology diagnostics, next-generation sequencing systems, and integrated laboratory informatics platforms. The contracting pattern indicates a preference for established, high-capacity vendors capable of delivering scalable, FDA-regulated solutions with robust technical support and compliance frameworks. Partnerships are characterized by long-term, performance-based agreements that prioritize reliability, regulatory alignment, and seamless integration with NIH research workflows. There is no set-aside preference evident in Mataya Robinson’s contracting activity; all awards are issued under full and open competition, indicating a focus on technical capability and scientific fit over socioeconomic classifications. This approach underscores a mission-driven prioritization of solution efficacy and operational readiness, with no formal targeting of 8(a), HUBZone, or SDVOSB programs. The procurement portfolio centers on diagnostic and life sciences technologies, with primary focus areas including clinical laboratory instruments, bioinformatics software, genomic analysis systems, and associated consumables. Robinson’s expertise lies in navigating the intersection of federal acquisition regulations and rapidly evolving biomedical innovation, ensuring that NCI’s research infrastructure remains at the forefront of cancer detection and therapeutic development.